HYTERRA LTD — Board/Management Information 2008

Jan 3, 2008

==> picture [116 x 105] intentionally omitted <==

==> picture [102 x 21] intentionally omitted <==

----- Start of picture text ----- www.brainz.com ARBN 116 829 675----- End of picture text -----

ASX Announcement

BrainZ transitions Board for next phase of growth

BrainZ welcomes new Chairman, Dr Damian Pethica

4 January 2008: BrainZ Instruments (ASX:BZI) announced today that life sciences specialist, Dr Damian Pethica, would be joining the Board as Chairman. At the same time, Mike Smith announced his resignation as both Chairman and a Director of the company.

BrainZ is extremely privileged to have the benefit of Dr Pethica’s expertise. Dr Pethica worked for Ciba-Geigy in Basel, Switzerland, as a group head in the medical department, pharmaceutical division, and then as Medical Director of Ciba-Geigy New Zealand. Following the merger of Ciba-Geigy and Sandoz, he became Medical Director of Novartis New Zealand. He subsequently joined Flemings in London as a biotechnology equities research analyst. After the acquisition of Flemings he became Vice President, Biotechnology Equity Research for Europe for JPMorganChase. Dr Pethica was educated at Oxford University (mathematics) and London University (medicine), and was in general medical practice for about seven years. He is a Fellow of the Faculty of Pharmaceutical Physicians, Royal College of Physicians London, a current authorised representative of JT Campbell & Co where he has previously provided research coverage on the company and is a current member of the Medicines Assessment Advisory Committee, New Zealand.

BrainZ would like to thank outgoing Chairman, Mike Smith, for his extraordinary efforts as founding Chairman of the company, and in particular for guiding the company to its initial public offering in 2005.

Dr Pethica will now lead the board as it directs the company into its next phase of growth, in particular focusing on various merger and acquisition opportunities.

Inquiries:

Richard Smith Chief Executive Officer BrainZ +1 443 280 2920

Rudi Michelson Monsoon Communications 03 9620 3333

About BrainZ

BrainZ (ASX: BZI) is a New Zealand based medical technology company specializing in the research, development, manufacturing and sale of bedside brain monitoring technology. The BRM2 Brain Monitor, BrainZ’s first product, is a unique bedside tool that assists in the detection of brain injury and seizure activity in neonates. It has been specifically designed to assist intensive care staff with clinical decision-making in conjunction with other clinical data and in the direction of care on a day-to-day basis.

The BRM2 monitor, and its successor the BRM3, have received regulatory approval in most major markets and are in use in over 20 countries worldwide. BrainZ dominates the local Australian and New Zealand markets via direct sales channels. BRM2 monitors are also installed in over 40 leading US hospitals. BrainZ has secured an exclusive agreement with GE Healthcare, a leading supplier of patient monitoring systems, for the distribution of BRM2 Brain Monitors in the USA and UK markets.

BrainZ Instruments was established in 2001 to commercialize pioneering neonatal brain research from the Auckland University’s Liggins Institute.